Logo

PanTherix, Genome Therapeutics Collaborate on Protein Structure Analysis for Drug Targets

Jan 23, 2003

NEW YORK, Jan. 23 - PanTherix and Genome Therapeutics said today they have entered a research collaboration in the search for drug targets.

 

Genome Therapeutics will use PanTherix's protein structure determination technology to unlock the three-dimensional structures of its bacterial targets in its anti-infective drug discovery program, the company said.

 

Financial terms of the agreement were not disclosed.

 

Click here for more information.

 

 

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.